Spero therapeutics to report fourth quarter and full year 2024 financial results and provide business update on thursday, march 27, 2025

Cambridge, mass., march 18, 2025 (globe newswire) -- spero therapeutics, inc. (nasdaq: spro), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (mdr) bacterial infections, today announced that it will report its financial results for the fourth quarter and full year ended december 31, 2024, and provide a business update, on march 27, 2025.
SPRO Ratings Summary
SPRO Quant Ranking